April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Half-life of therapeutic molecules in the vitreous depends on molecular weight, vitreous network mesh size and eye size
Author Affiliations & Notes
  • Michael Monine
    Advanced Quantitative Sciences, Novartis, Cambridge, MA
  • Matthias Machacek
    Advanced Quantitative Sciences, Novartis, Basel, Switzerland
  • Footnotes
    Commercial Relationships Michael Monine, Novartis (E), Novartis (F); Matthias Machacek, Novartis (E), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 444. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Monine, Matthias Machacek, ; Half-life of therapeutic molecules in the vitreous depends on molecular weight, vitreous network mesh size and eye size. Invest. Ophthalmol. Vis. Sci. 2014;55(13):444.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

A long ocular half-life contributes to long effect duration and is critical for biotherapeutics to avoid frequent intravitreal injections. For the development of novel biotherapeutics it is therefore important to understand the process of ocular disposition, the factors dominating half-life and how animal data translates to human.

 
Methods
 

A biophysical model was used to investigate diffusion-driven distribution and clearance of molecules in the eye. The model was calibrated with fluorophotometry data obtained for tagged Fab fragment injected in rabbit eyes and validated against published rabbit and human data which included small molecules, scFv, Fab fragments, Fc fusion proteins and antibodies covering a molecular weight (MW) range of 100 to 150’000 Da.

 
Results
 

The model predicted well the dependency on MW supporting that diffusion is a key process of clearance (Figure 1 A). The main factors contributing towards a longer half-life were a higher MW, a smaller mesh size of the vitreous network and a larger eye. These results also suggested that differences in eye size (Figure 1 B) and in vitreous mesh size are among main factors in translating half-life data from animal to human.

 
Conclusions
 

A biophysical model provides a basis for mechanistic interpretation of ocular PK data in animals and can be used to predict the ocular half-life in human and guide optimal design and selection of long acting molecules.

 
 
Figure 1: (A) Vitreal half-life as a function of MW: literature data vs. model prediction in the rabbit eye. (B) Comparison of the data and the model predictions for biotherapeutics injected in rabbit and human eyes. Solid lines denote model predictions assuming the average vitreous network mesh size equal to 100 nm. Shaded area in panel A covers a range of mesh sizes from 30 nm (upper boundary) to infinity (lower boundary, diffusion in water).
 
Figure 1: (A) Vitreal half-life as a function of MW: literature data vs. model prediction in the rabbit eye. (B) Comparison of the data and the model predictions for biotherapeutics injected in rabbit and human eyes. Solid lines denote model predictions assuming the average vitreous network mesh size equal to 100 nm. Shaded area in panel A covers a range of mesh sizes from 30 nm (upper boundary) to infinity (lower boundary, diffusion in water).
 
Keywords: 412 age-related macular degeneration • 763 vitreous • 473 computational modeling  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×